Patents Assigned to Merck
  • Pyrrolidine modulators of chemokine receptor activity
    Patent number: 6498161
    Abstract: The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.
    Type: Grant
    Filed: April 4, 2000
    Date of Patent: December 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Charles G. Caldwell, Kevin T. Chapman, Jeffrey Hale, Dooseop Kim, Christopher Lynch, Malcolm MacCoss, Sander G. Mills, Christopher Willoughby, Scott Berk, Ronald M. Kim
  • Nematic liquid-crystal composition
    Patent number: 6497828
    Abstract: The invention relates to nematic liquid-crystal compositions comprising bisalkenyl compounds of the formula Ia. in which R1 and R2, are each independently alkenyl having 2 to 8 carbon atoms, and Z2 is a single bond, —(CH2)2— or trans-CH═CH—. and to their use in plasma-addressed LCDs.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: December 24, 2002
    Assignee: Merck Patent GmbH
    Inventors: Harald Hirschmann, Sven Schüpfer, Marcus Reuter
  • Src kinase inhibitor compounds
    Patent number: 6498165
    Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: December 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Helen M. Armstrong, Richard Beresis, Joung L. Goulet, Mark A. Holmes, Xingfang Hong, Sander G. Mills, William H. Parsons, Peter J. Sinclair, Mark G. Steiner, Frederick Wong, Dennis M. Zaller
  • Colored pigments
    Publication number: 20020192448
    Abstract: The present invention relates to colored pigments based on multicoated platelet-shaped substrates which are distinguished by the fact that they comprise
    Type: Application
    Filed: April 24, 2002
    Publication date: December 19, 2002
    Applicant: Merck Patent GmbH
    Inventors: Sabine Schoen, Christoph Schmidt
  • Eosinophil eotaxin receptor
    Publication number: 20020192214
    Abstract: The eosinophil eotaxin receptor has been isolated, cloned and sequenced. This receptor is a human &bgr;-chemokine receptor and has been designated “CC CKR3”. The eosinophil eotaxin receptor may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor. Such compounds would be useful in the treatment and prevention of atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and particularly bronchial asthma.
    Type: Application
    Filed: August 6, 2001
    Publication date: December 19, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Bruce L. Daugherty, Julie A. Demartino, Salvatore J. Siciliano, Martin S. Springer
  • Electrophotographic dry toner comprising angle-dependent luster pigments
    Publication number: 20020192585
    Abstract: The invention relates to a dry toner for laser printing which comprises at least one viewing angle-dependent (“angle-dependent”), platelet-shaped luster pigment. The luster pigment consists of a multicoated, platelet-shaped, opaque or semi-transparent substrate. The toner is particularly suitable for security printing. The invention furthermore relates to a process for the production of images by electrophotographic methods using the dry toner.
    Type: Application
    Filed: May 20, 2002
    Publication date: December 19, 2002
    Applicant: Merck Patent GmbH
    Inventors: Gunter Brenner, Hans-Dieter Bruckner, Wolfgang Hechler, Burkhard Krietsch, Matthias Kuntz, Michael Schmelz
  • Thienopyrimidines
    Patent number: 6495554
    Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: December 17, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Synthesis of ketosulfone esters
    Patent number: 6495713
    Abstract: This invention encompasses a process for making a compound of Formula A These compounds are intermediates useful in the preparation of certain non-steroidal anti-inflammnatory agents.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: December 17, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Cheng Yi Chen, Weirong Chen, Paul O'Shea, Lushi Tan, Richard Tillyer, Feng Xu, Philippe Dagneau
  • NPY Y5 receptor antagonists
    Patent number: 6495559
    Abstract: Compounds of general structural formula I such as that shown in structural formula II are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: December 17, 2002
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Ying-Duo Gao, Douglas J. MacNeil, Lihu Yang, Nancy R. Morin, Takehiro Fukami, Akio Kanatani, Takahiro Fukuroda, Yasuyuki Ishii, Masaki Ihara
  • 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
    Patent number: 6495561
    Abstract: 4-substituted cyclohexanes substituted in the 1-position with imidazopyridine either directly or through a C1-C4alkyl, C1-C4alkenyl, C1-C4alkynyl, C1-C4alkoxy, amino, aminoC1-C4alkyl, hydroxyC1-C4alkyl, carbonyl, cycloC3-C6alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: December 17, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Wayne J. Thompson, David A. Claremon, Peter M. Munson, John A. McCauley
  • Biocements having improved compressive strength
    Patent number: 6495156
    Abstract: The invention describes biodegradable calcium phosphate cements, in particular mixtures of calcium phosphate-containing powders of different stoichiometric composition, the precipitated hydroxylapatite present being a cation-deficient hydroxylapatite of the formula 1, with the result that the mixtures have improved properties with regard to compressive strength.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: December 17, 2002
    Assignee: Merck Patent GmbH
    Inventors: Robert Wenz, Ferdinand Driessens
  • Isoforms of mouse serotonin 5-HT2C receptor
    Patent number: 6495665
    Abstract: The invention includes mouse serotonin 5-HT2c receptor isoforms having amino acid replacements at one or more positions of the natural mouse serotonin 5-HT2c receptor polypeptide sequence, specifically at one or more of positions 157, 159 and 161. The polypeptides are useful for identifying ligands which bind with the serotonin 5-HT2c receptor and modulators of the serotonin 5-HT2c, and for identifying drugs with affinity for 5-HT2 receptors which are used to treat schizophrenia, Parkinsonism, and anxiety disorders.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: December 17, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Tong M. Fong, Jie Liu, Leonardus H. T. Van Der Ploeg
  • Energy dispersion x-ray fluorescence analysis of chemical subtances
    Patent number: 6496562
    Abstract: The invention relates to a method for classifying and identifying by means of energy dispersion X-ray fluorescence analysis chemical substances whose X-ray fluorescence lines cannot be detected and which therefore cannot be classified by energy dispersion X-ray fluorescence analysis alone. Said method is characterized in that the sample to be analyzed is analyzed in its original packaging or natural state without prior processing in a sample vessel. According to the method the sample is: a) positioned in front of the measuring aperture in a sample chamber of an X-ray fluorescence apparatus; b) measured; and c) classified and identified by application of multivariate, statistical techniques to the measurement signals obtained, i.e., to the Compton and Rayleigh scattering.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: December 17, 2002
    Assignee: Merck Patentgesellschaft mit Beschrankter Haftung
    Inventors: Alexander Henrich, Hans-Helmut Itzel, Peter Hoffmann, Hugo Ortner
  • Chiral compounds
    Patent number: 6495217
    Abstract: The invention relates to chiral compounds of formula I wherein R1, R2, X, Y1 and Y2 have the meanings defined herein, as well as to liquid crystalline mixtures comprising at least one chiral compound of formula I.
    Type: Grant
    Filed: October 4, 1999
    Date of Patent: December 17, 2002
    Assignee: Merck Patent GmbH
    Inventor: Louise Farrand
  • Condensed thienopyrimidines with phosphodiesterase-v inhibiting action
    Patent number: 6495557
    Abstract: Thienopyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2 and X have the meanings given in claim 1, inhibit phosphodiesterase V and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impaired potency.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: December 17, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Pharmaceutical tablets
    Publication number: 20020187186
    Abstract: The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.
    Type: Application
    Filed: March 15, 2002
    Publication date: December 12, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Tzyy-Show H. Chen, Thomas G. Nyairo, Ashok V. Katdare
  • Pharmaceutical levothyroxine preparation
    Patent number: 6491946
    Abstract: The invention relates to a pharmaceutical preparation comprising levothyroxine sodium, potassium iodide, microcrystalline cellulose and binding agent, which is free of antioxidants or further auxiliaries, and processes for its production.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: December 10, 2002
    Assignee: Merck Patent Gesellschaft
    Inventors: Sven Schreder, Marion Nischwitz
  • Stable cosmetic formulation containing butylmethoxydibenzoylmethane
    Patent number: 6491930
    Abstract: The invention relates e.g. to the use of aldehydes and/or ketones for improving the stability of cosmetic formulations containing butylmethoxydibenzoylmethane as organic light protection filters in conjunction with inorganic light protection filters.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: December 10, 2002
    Assignee: Merck Patent Gesellschaft MIT
    Inventors: Thekla Kurz, HansJürgen Driller, Sabine Hitzel, Dorothee Wille
  • Benzamidine derivatives as factor XA inhibitors
    Patent number: 6492368
    Abstract: Novel compounds of the formula I in which X, Y, R1, R2 and R3 are as defined in Patent Claim 1 are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: December 10, 2002
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Hanns Wurziger, Guido Melzer, Horst Juraszyk, Sabine Bernotat-Danielowski
  • Imidazo (4,5-C) pyridine-4-one derivatives with factor XA inhibiting effect
    Patent number: 6492384
    Abstract: The invention relates to novel compounds of formula (I), wherein R, R1, R2, R3, n and p have the meaning defined in claim 1. Compounds are inhibitors of clotting factor Xa and can be used for the prophylaxis and/or therapy of thrombo-embolic disorders.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: December 10, 2002
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Horst Juraszyk, Hanns Wurziger, Joachim Gante, Dieter Dorsch, Hans-Peter Buchstaller, Sabine Bernotat-Danielowski, Guido Melzer, Soheila Anzali